ライフサイエンスコーパス: sitaxsentan

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 were elevated at baseline and decreased with sitaxsentan.

2 Sitaxsentan (1) is our first endothelin antagonist being

3 were randomized to receive placebo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n =

4 At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compare

5 or placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.

6 ctive therapy (101 [15%] iloprost, 118 [18%] sitaxsentan, 204 [31%] sildenafil, and 233 [36%] subcuta

7 Sitaxsentan (3, TBC11251) is an orally active ET(A) sele

8 bo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n = 63) orally once daily for 12 wee

9 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6M

10 The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosen

11 limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% fo

12 determined the acute hemodynamic effects of sitaxsentan, a selective ET(A) receptor antagonist, in p

13 The selective ET A receptor antagonist sitaxsentan also improves hemodynamics and exercise capa

14 selective endothelin receptor-A antagonists sitaxsentan and ambrisentan are currently undergoing inv

15 used the selective ET(A) receptor antagonist sitaxsentan at increasing rates (0.3125 to 10 mg/min) in

16 In patients with HF, sitaxsentan caused an infusion rate-dependent decrease i

17 Sitaxsentan decreased pulmonary artery systolic pressure

18 s exercise, TBC3214 (17) was identified as a sitaxsentan follow-on candidate.

19 ive endothelin A (ET(A)) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hype

20 udy, the selective ET(A) receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World

21 cardiac index, and MPAP were not affected by sitaxsentan in either group.

22 In contrast, sitaxsentan infusion had no effect on local PVR in contr

23 Sitaxsentan may be of value in the treatment of patients

24 Sitaxsentan may benefit patients with pulmonary arterial

25 to 1 of 3 doses (1.5, 3.0, or 6.0 mg/kg) of sitaxsentan or placebo as an intravenous infusion over 1

26 with the selective ET(A) receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, impr

27 istration of the selective ET(A)R antagonist sitaxsentan prevented podocyte loss, formation of the hy

28 ion trial, once a day treatment of 100 mg of sitaxsentan statistically significantly improved 6-min w

29 agonism and the subsequent identification of sitaxsentan (TBC11251, 1) as a clinical development comp

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。